Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR): A Randomized Multi-center Study for Men With Newly Diagnosed Favorable Risk Prostate Cancer


Condition: Prostate Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT04396808

Sponsor: University of Michigan Rogel Cancer Center

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • Prostate cancer patients who have undergone diagnostic prostate biopsy in the past 9 months.
  • Prostate biopsy tumor tissue (FFPR block) available for processing
  • Age 18 years or older
  • PSA <20 ng/ml
  • Grade Group (GG) 1 cancer with > 2 biopsy cores involved with cancer OR GG2 cancer
  • Ability to understand and the willingness to sign a written informed consent. A subject's legally acceptable representative may sign the consent form.

Exclusion Criteria:

  • Clinical (on digital rectal exam) or radiographic evidence (if MRI performed) of T3 disease
  • Nodal or metastatic prostate cancer (if staging imaging performed)
  • Prior prostate cancer treatment, including prostatectomy, radiation therapy, or hormone therapy.
  • Prior prostate gene expression classier testing

View trial on ClinicalTrials.gov